On September 17, 2024, Neo Medical SA (Neo), a Swiss technology company specializing in spine surgery, announced the successful completion of its Series B financing round, including the conversion of existing shareholder loans. With this financing round, Neo has secured an additional equity investment of up to $68 million to accelerate its global growth. Led by Gyrus Capital SA (Gyrus), alongside the participation of existing investors, including founders Vincent Lefauconnier and Jonas Larsson, this round is one of the most significant in the spine industry in the last decade. The proceeds will be used to increase Neo’s market share in key regions with an immediate focus on expanding the U.S. business, deploying new, complementary, and disruptive products, and enhancing the capabilities of its unique AIdriven augmented reality intraoperative data platform, ADVISE™.

Wilson Sonsini Goodrich & Rosati advised Neo Medical on U.S. aspects of the financing, focusing largely on patent strategy. The patent team was led by Matthew Bresnahan, Darby Chan, and Nima Zargari. In addition, Wilson Sonsini historically has assisted Neo Medical with strategic corporate advice, led by Marty Waters.

For more information, please see Neo Medical's press release.